Real-World SCFF vs Intestinal Levodopa: High Dropout, Clinician-Patient Mismatch
This single-center retrospective cohort adds real-world discontinuation, adverse event, and efficacy-perception data for subcutaneous foslevodopa-foscarbidopa alongside intestinal levodopa gel, informing counseling and monitoring for pharmacists supporting device-assisted Parkinson's disease therapy.
📅 Journal publication: Jul 2026(online Feb 11, 2026)·Last updated: Nov 20, 2026
High dropout rates challenge the promise of novel PD therapies.
Subcutaneous foslevodopa-foscarbidopa (SCFF) is a novel non-surgical option for advanced Parkinson's disease, but lacks real-world data. SCFF showed real-world efficacy, but 33% withdrew within 4 weeks; patient-clinician efficacy perceptions differed significantly. The findings highlight the need for systematic management guidelines for SCFF amid high dropout and perception discrepancies. SCFF may control motor fluctuations in advanced PD, but structured management is needed due to high early dropout rates.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Hartig J, Sitzmann L, Hartenstein D, Labisch M, Ip CW, Volkmann J, Daniels C
Citation:Hartig J, Sitzmann L, Hartenstein D, et al. Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real-World, Monocentric, Observational Study and Critical Review. Movement disorders clinical practice. 2026;13(7):1662-1672. doi:10.1002/mdc3.70557